Whole Body Digital Twin is a dynamic digital tool that provides precise guidance to enable reversal and prevention of chronic metabolic disease
Twin Health will scale its Whole Body Digital Twin. (Credit: Myriams-Fotos from Pixabay.)
Twin Health has raised $140m in Series C financing round to scale its ‘Whole Body Digital Twin’ service for chronic metabolic disease.
Investors including ICONIQ Growth, Sequoia Capital India, Perceptive Advisors, Corner Ventures, LTS Investments, Helena and Sofina have participated in the funding round.
Twin Health is a precision health platform that comprises IoT sensors, machine learning, and medical science to improve human metabolic health.
Its Whole Body Digital Twin is a predictive digital tool that provides personalised nutrition, sleep, activity and breathing guidance through an easy-to-use app.
ICONIQ founding partner Divesh Makan said: “We are delighted to partner with the visionary Jahangir Mohammed and his exceptional team as they scale Twin Health and its groundbreaking technology to address one of the biggest healthcare challenges of our time.
“Twin Health has the opportunity to transform and improve the quality of life for so many people, and we are incredibly proud to support the company’s mission.”
According to the company, Whole Body Digital Twin facilitates reversal and prevention of chronic metabolic diseases, while improving energy and physical health.
The digital tool was created using a large volume of data points collected through non-invasive wearable sensors and self-reported preferences and is backed by artificial intelligence (AI).
It continuously monitors the health of the individual and enables healthcare providers and Twin coaches to take action rapidly.
Twin Health founder and CEO Jahangir Mohammed said: “Our Whole Body Digital Twin lives alongside you, giving you a view into your beautifully complex biology, continuously learning about your metabolism and telling you what you can do to improve your health in the moment.”
Furthermore, the company’s clinical research team is conducting a randomised controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology.
In the early RCT data, patients had an average HbA1c reduction from baseline, with more than 90% reversal of type 2 diabetes, eliminating diabetes medications including insulin.